选择性增加PTV单次剂量对食管癌患者预后的影响
DOI: 10.3971/j.issn.1000-8578.2019.18.2007
Keywords: A Meta-analysis,Value of 18F-FDG PET/CT in Evaluating Chemotherapeutic Effect of Diffuse Large B Cell Lymphoma Patients with Different CD5 Expression,Advances in Prognostic Value of Peripheral Blood Inflammatory Indexes in Non-small Cell Lung Cancer,Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castrationresistant Prostate Cancer Patients,Cholesterol: A Predictor of Risk and Prognosis of Breast Cancer,Predictive Value of Preoperative Hematologic Inflammatory Markers in Prognostic of Glioma Patients,Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix,Effect of Marital Status on Survival of Lung Cancer Patients Investigated Based on SEER Database,Clinical Characteristics and Prognosis of Primary Thyroid Lymphoma Patients,Prognostic Factors and Comprehensive Treatment of 95 Synovial Sarcoma Patients,Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
Abstract:
摘要 目的 探讨选择性增加PTV单次剂量对食管癌患者预后的影响。方法 收集接受治疗的食管癌患者302例，进行预后影响因素分析，并比较不同PTV单次剂量的两组患者的构成比，依据Cox多因素分析结果，应用PSM法进行1:1匹配，分析匹配后两组患者的预后影响因素。结果 全组患者中位OS为30.0月（HR: 3.319, 95%CI: 23.495~36.505），中位DFS为21.3月（HR: 1.838, 95%CI: 7.698~24.902）。多因素分析结果显示，化疗、cTNM分期和PTV单次剂量为OS（均P<0.05）和DFS（均P<0.05）的独立预后影响因素。依据多因素分析结果进行PSM分析，经1:1配比后每组患者90例。PSM后多因素分析结果显示，cTNM分期和PTV单次剂量为患者OS独立预后影响因素；化疗、cTNM分期和PTV单次剂量为患者DFS独立预后影响因素；两组患者≥2级急性不良反应发生率差异无统计学意义（均P>0.05）。SIB-IMRT组中PTV单次剂量为2 Gy和>2 Gy的患者亚组分析结果显示，后者的OS和DFS均显著性优于前者（均P<0.05 ）。结论 选择性增加PTV单次剂量可改善接受根治性放（化）疗食管癌患者的生存情况，而不增加其不良反应
Full-Text
